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Abstract

their high specificity and low toxicity as compared to
that of small organic molecules (10).
Several groups have developed amyloid aggregation mitigating peptides (AAMPs) based on designed
changes to the Αβ16-20 central hydrophobic core,
KLVFF fragment, which Tjenberg (11, 12) showed
to be critical for Aβ self-assembly and self-recognition.
To the KLVFF core, a “disrupter” group is added that
either solubilizes inhibitor-Aβ aggregates or blocks
further addition of β-sheets through hydrogen bonding.
Disrupters that have been added to peptides can be
classified as N- or C-terminal modifications (13), conformationally constrained amino acids (14), peptide
backbone modifications (15), or as the use of D-amino
acids (16).
An example for C-terminal modifications was the
addition of oligolysine chains to the C-terminus of the
KLVFF motif to design the peptide KLVFFKKKKKK, which was shown to enhance the rate of Aβ1-40
aggregation into fibrils and thereby prevent toxicity
against PC12 cells (13, 17). Also, the rate of Aβ assembly
into fibrils was shown to depend on the number of lysine
groups present in the mitigator. Several modifications of
the peptide backbone for the KLVFF binding motif
have been reported. These include the replacement
of amide hydrogen with methyl groups (15, 18) and
replacement of the amide bond with either an ester
bond (19) or isostructural E-olefin (20). These modifications were designed to block the proliferation of hydrogen-bonding between β-sheets that is necessary for Aβ
fibrillization. Peptides derived from these modifications were found to disrupt Aβ1-40 fibril formation
and to disassemble preformed fibrils. For instance,
N-methylated peptide Aβ16-22m (15) and esterificated
Aβ16-20e (19) disrupted fibril formation and caused
the disassembly of preformed fibrils. Also, it was demonstrated that mutations of the Phe19-Phe20 amide
bond of Aβ1-40 with an E-olefin bond exclusively
produced spherical aggregates and that fibrillization
was not detected despite incubation periods of up to
6 weeks (20, 21).

Considerable research effort has focused on the discovery of mitigators that block the toxicity of the βamyloid peptide (Aβ) by targeting a specific step
involved in Aβ fibrillogenesis and subsequent aggregation. Given that aggregation intermediates are hypothesized to be responsible for Aβ toxicity, such
compounds could likely prevent or mitigate aggregation, or alternatively cause further association of toxic
oligomers into larger nontoxic aggregates. Herein we
investigate the effect of modifications of the KLVFF
hydrophobic core of Aβ by replacing N- and C-terminal groups with various polar moieties. Several of
these terminal modifications were found to disrupt
the formation of amyloid fibrils and in some cases
induced the disassembly of preformed fibrils. Significantly, mitigators that incorporate MiniPEG polar
groups were found to be effective against Aβ1-40 fibrilligonesis. Previously, we have shown that mitigators
incorporating alpha,alpha-disubstituted amino acids
(RRAAs) were effective in disrupting fibril formation
as well as inducing fibril disassembly. In this work, we
further disclose that the number of polar residues (six)
and RRAAs (three) in the original mitigator can be
reduced without dramatically changing the ability to
disrupt Aβ1-40 fibrillization in vitro.
Keywords: Amyloid peptide (Aβ), fibrils, spherical
structures, mitigators, assembly, disassembly

A

standing hypothesis associated with Alzheimer’s disease (AD) is that aggregation of
monomeric β-amyloid (Aβ) fibrils into the
neurotoxic misfolded forms is the key event associated
with the disease pathogenesis (1-3). Recently, extensive
investigation of the aggregation pathway reveals that
oligomeric assemblies and not mature fibrils are responsible for Aβ neurotoxicity (4-9). Several approaches
have been designed to target the Aβ assembly process in
an effort to reduce toxic species in the brain. Peptidebased approaches in particular are increasingly becoming a vital constituent of new therapeutics because of
r 2010 American Chemical Society
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evaluate the effectiveness of reducing the overall charge
of the mitigator. Also, the effects of RRAA-containing
AAMPs with fewer polar groups as compared to those
of the original mitigator AAMP-1 with six Lys are
presented.
Peptide analogues modified with R-amino isobutyric
acid (also called R-methyl alanine) have been shown
to be more effective at inducing the disassembly of Aβ
fibrils than either L-proline or D-amino acids in short
model peptides (28, 29). The restrictions imposed by
R-methyl alanine or C-R-tetra-substituted-amino acid
on conformational freedom are more severe than those
of proline. Thus, mitigators containing bulky substituents (RRAAs) could be more effective at inducing
β-sheet disassembly than peptides that incorporate proline. Simulation experiments have shown that N-methylated peptide Aβ16-22m interacts with the Aβ16-22
blocking β-sheet extension, preventing lateral association into layers, and more importantly blocking inhibitor intercalation for sequestering Aβ peptides. However,
Aβ16-22m has also been to shown in vivo to increase
Aβ deposition in the brain of APP transgenic mice,
unlike our peptide AMY-1 which showed ability to
reduce Aβ deposits. Our RRAAs are bulkier than either
N-methylated or R-methyl alanine model peptide derivatives. Thus, we hypothesize that RRAA-AAMPs
could be more effective at both disrupting fibril formation as well as inducing the disassembly of preformed
fibrils.

Conformationally constrained peptides have been
shown to be effective at disrupting Aβ fibril formation
through unfavorable steric interactions. For instance, a
β-sheet breaker peptide, iAβ5 containing one proline
residue was shown to disrupt fibril formation, disassemble preformed fibrils, and protect against neurotoxicity (22). Our approach for this report involves replacing
the hydrogen atom of the R-carbon of natural amino
acid residues (to form alpha,alpha-disubstituted amino
acids, RRAAs) in the KLVFF motif with an alkyl
substituent. Thus, the conformational freedom of the
peptide is restricted, and it is forced to adopt an extended conformation that is ideal for interaction with
Aβ1-40 (23, 24). Peptides in an extended conformation
form two faces where one face is available for interaction
with Aβ, while the other is sterically blocked, limiting
β-sheet extensions required for amyloid fibril propagation.
Apart from blocking hydrogen bonding between
β-sheets, incorporation of RRAAs within the KLVFF
motif also increases the overall hydrophobicity of the
mitigator peptide and in turn strengthens the hydrophobic interactions with the Aβ1-40 target. Polar groups
are normally added to the highly hydrophobic RRAAcontaining KLVFF core to increase the overall solubility of the peptide. Also, modification of the R-carbon
helps to decrease susceptibility of the mitigator to proteolytic degradation, which ensures effective delivery of
the inhibitor to the target organ during in vivo studies. In
general, our design for mitigators combines the advantages of both C-terminal and R-carbon modification.
We have previously developed a mitigator peptide
(AMY-1) with a C-terminal oligolysine chain (KDibgVDbgFDpgK 6 ) and a peptide (AMY-2) with an
N-terminal oligolysine chain (K7KDibgVDbgFDpg).
Both mitigator peptides AMY-1 and AMY-2 disrupted
fibril formation and formed spherical aggregates of
different heights (25). We have shown that AMY-1
has the ability to reduce Aβ deposits when injected into
the hippocampus of 14-month-old APP transgenic mice,
a model of amyloid deposition (26). Although, AMY-1
showed tendencies to reduce Aβ deposits, it was toxic at
high doses. We postulate that AMY-1 toxicity is due to
either the overall charge from the six lysines or due to the
size of the mitigator, which might hinder its movement
across the brain barrier. Thus, the charge and molecular
weight of the mitigator should be reduced for optimal
use in vivo and improved systemic bioavailability.
Incorporation of one or two RRAAs in the KLVFF
binding motif was previously shown to be effective at
disrupting Aβ1-40 fibrillization as compared to the
original peptide (AAMP-1) with three RRAAs (27).
Herein, the effects of forming Aβ fibrils in the presence of amyloid aggregating mitigating peptides
(AAMPs) incorporating different polar solubilizing
groups (C- or N-terminal) are studied in an effort to
r 2010 American Chemical Society

Results and Discussion
Design of Peptides for Mitigating Aβ Aggregation
Initial work by Tjenberg identified the Aβ central
hydrophobic core KLVFF as the key scaffold for
designing disrupters of Aβ1-40 fibrillization (11, 12).
Disrupting elements have been strategically placed at
various positions within the Aβ hydrophobic core that
either solubilize the AAMP-Aβ aggregate (Lys or Arg)
or block one hydrogen boding face inhibiting β-sheet
extension or propagation as with N-Me amino acid or
ester bonds. Thus, polar groups such as Arg, Lys, Glu,
and PEG chains were added to increase the solubility of
peptides. Certain mitigators incorporating these polar
groups have been shown to be effective at disrupting
fibril formation (17).
Surface plasmon resonance (SPR) was employed by
Murphy and co-workers (30) to study the binding of
variants related to KLVFF on immobilized Aβ10-35
fibrils (12). Variants with positively charged residues
(KLVFFKn) added to the C-terminus had higher affinities for immobilized Aβ10-35 fibrils than the KLVFF
control, while negatively charged residues (KLVFFEn)
also placed on the C-terminus had a significantly lower
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binding affinity. In contrast, N-terminal addition of
positively charged residues (KnKLVFF) resulted in
lower affinity. Binding affinity also is affected by additions of polar groups that do not precede the KLVFF
region in the parent Aβ sequence. Therefore, amino
acids (for example Gly) that are conformationally unrestricted can be used as a spacer between the KLVFF
motif and solubilizing residues. Using Gly as a spacer
between the mitigator KLVFF core and Arg residues
(solubilizing agents) on both the C- and N-termini,
Austen et al. designed the peptide RGKLVFFGR (31).
This peptide was shown to be an effective disrupter of
Aβ1-40 fibril formation and to prevent neurotoxicity
toward human neuroblastoma SHSY5Y cells.
As part of our continuing work to design more
effective RRAA-containing AAMPs (14), we employed
similar strategies for placing spacers between the AAMP
core KLVFF and the solubilizing groups. We have
previously shown that AAMP-1 disrupted Aβ fibril
formation (25). In vivo studies of AAMP-1 on APP
transgenic mice displayed elevated toxicity at higher
concentrations (32). The toxicity observed could be
related to the six cationic lysines which also affect the
delivery of drugs across the hydrophobic brain barrier
during in vivo studies. Thus, positively and negatively
charged polar amino acids as well as neutral polar
groups such as MiniPEG were evaluated for effects on
the morphology of resulting nanoparticles. Our goal
was to reduce the overall charge of the original peptide
(AAMP-1) without sacrificing the mitigator ability to
disrupt fibril formation and induce disassembly of preformed fibrils.
Our design of mitigators is based on the much
described Aβ central hydrophobic core. Solubilizing polar residues were added to this core, however,
with a spacer in between them as previously described
by Austen and co-workers (31). Several peptide mitigators (Table 1) were designed to probe the effect
of various polar groups (positive, negative, or neutral)
and/or substitution of natural amino acids with R,Rdisubstituted amino acids on Aβ1-40 fibrillization. Peptide mitigator AAMP-11 described by Austen and coworkers was used as a control peptide. First, the effect of
various polar groups on Aβ1-40 aggregation was investigated by designing mitigators where Arg (control
peptide) is replaced with Lys (AAMP-12), Glu (AAMP13), and MiniPEG (AAMP-14) (Table 1). Mitigator
AAMP-15 allowed us to probe the effect of increasing
the number of Arg in the chain to three on both the
C-and N-terminus on Aβ fibrillogenesis. Peptide mitigators AAMP-16, AAMP-17, and AAMP-18 were designed to evaluate the effect of placing polar groups Arg,
MiniPEG, and Lys, respectively, on only the C-terminus. The effect of placing polar groups on the N-terminus was evaluated using AAMP-19 with Arg added only
r 2010 American Chemical Society

Table 1. Modified AAMPs Used to Probe the Assembly and Dissolution of Aβ Fibrils
AAMP

sequence

AAMP-11

RGKLVFFGR

AAMP-12

KGKLVFFGK

AAMP-13

EGKLVFFGE

AAMP-14

(MiniPEG)GKLVFFG(MiniPEG)

AAMP-15

RRRGKLVFFGRRR

AAMP-16
AAMP-17

KLVFFGR
KLVFFG(MiniPEG)

AAMP-18

KLVFFGK

AAMP-19

RGKLVFF

AAMP-20

KLVFFDpgGK

AAMP-21

KGKDibgVFFGK

AAMP-22

KDibgVFFDpgGKKK

AAMP-23

KKKGKLVFFDpgGKKK

AAMP-24
AAMP-25

KDibgVFFGKKK
KLVFFFDpgGKKK

Aβ16-22m

K(Me)LV(Me)FF(Me)AE

to the N-terminus. We have previously shown that one,
two, or three RRAAs incorporated in a mitigator sequence with six C-terminal lysines was efficient in disrupting the process of Αβ fibrillization (27, 33). Thus,
mitigators AAMP-20, AAMP-21, AAMP-22, AAMP23, and AAMP-24 were designed to probe the effect of
reducing both the number of RRAAs as well as lysines
on Aβ fibrillization. We hypothesize that the addition
of a spacer between the RRAA-containing KLVFF
mitigator core and solubilizing residues would improve
the interaction between the AAMP and the Αβ full
sequence length. The N-methylated peptide, Αβ1622m previously described to disrupt fibril formation
and disassemble preformed fibrils was used as a control
peptide because it is similarly designed to block one
hydrogen face from β-sheet extension and packing.

Effects of AAMPs on Aβ1-40ThT Fluorescence
Thioflavin T undergoes a characteristic spectral
change upon binding to fibrillar species, with maximum
emission shifting from 445 to 482 nm (34-36). The
intensity of ThT fluorescence is directly proportional to
amyloid fibril formation. However, it has also been
shown that fluorescence can result from ThT dye binding to amorphous aggregates though with less intensity (20, 37). Despite this, ThT is useful for following real
time formation of amyloid structures and studying the
aggregation kinetics. Prior to investigating the effects of
AAMPs on Aβ1-40 aggregation, the individual peptides
were first tested alone to evaluate tendencies to selfaggregate. The individual AAMP solutions were aged in
80 μM PBS (pH 7.4) for 1 week at 37 °C with periodic
agitation. Under these conditions, all of the AAMPs
exhibited <10% reduced fluorescence relative to that of
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ThT fluorescence (60-80%) as compared to that of the
corresponding mitigators with polar groups added to both
C- and N-termini (40-70%). For instance, the addition of
the Arg residue to only the C-terminus in AAMP-16 was
found to exhibit 80% reduced ThT fluorescence. Other
AAMPs in the series incorporating MiniPEG (AAMP-17)
and Lys (AAMP-18) exhibited a 60% reduction of ThT
fluorescence after 1 week of incubation. This suggests a
possible effect of terminal polar group position on Aβ1-40
fibril formation. However, placing the polar group on the
N-terminus, for instance Arg in AAMP-19, showed
a reduced fluorescence of 40% as compared to 80% when
Arg (AAMP-16) was placed on the C-terminus. This
suggests also a difference in the amount or morphology
of the amyloid structures formed.
Mitigators incorporating RRAAs and differing numbers of polar residues that were designed to optimize
the charge and size of the original mitigator also exhibited reduced fluorescence. The mitigators AAMP-20,
AAMP-21, AAMP-24, and AAMP-25 were found to
reduce Aβ1-40 fluorescence by less than 40%, whereas
AAMP-22 and AAMP-23 exhibited 80% reduced ThT
fluorescence. On the basis of ThT results, only AAMP11, AAMP-16, AAMP-22, and AAMP-23 exhibited a
higher reduction in ThT fluorescence relative to Aβ1-40
than the N-methylated peptide, Aβ16-22m previously
reported to disrupt fibril formation and to disassemble
preformed fibrils (15).
As previously described by Austen and co-workers (31)
AAMP-11 was found to inhibit oligomer formation
and prevent Aβ1-40 toxicity toward neuroblastoma SH5Y5Y cells. They reported that an equimolar mixture
of Aβ1-40/AAMP-11 aged for 12 days under quiescent
conditions showed reduced fluorescence of over 80%
relative to that of Aβ1-40 (31). For the same peptide after
7 days aging, however, we report insignificantly lower
ThT fluorescence of 63% with periodic sample agitation,
as compared to the previously reported result of over
80% reduction under quiescent conditions. Agitation is
normally employed to enhance Aβ aggregation enabling
analysis on a laboratory time scale, although the fibrils
formed are less stable and more toxic (38, 39). Also, a
crossover experiment was done with selected AAMPs
against an Aβ1-42 isoform known to be more toxic and
with faster aggregation kinetics than Aβ1-40, hence
limiting its use in kinetics experiments. The AAMPs
tested showed disruptive trends (see Supporting Information, Figure S2) similar to those observed with
Aβ1-40 suggesting the same mitigator binding site
(Aβ1-40 central hydrophobic core) as expected and
hence identical disruption.

Figure 1. Time dependent ThT fluorescence assay of Aβ/AAMPs.
(The final concentration was 40 μM for both Aβ1-40 and AAMPs.)

Aβ1-40 suggesting minimal formation of thioflavin T
active structures.
When Aβ1-40 was aged alone, it showed timedependent increases in fluorescence intensity, indicating
aggregation into amyloid fibrils. However, when aged
with the various AAMPs at 1:1 molar ratios (40 μM
final concentration) with periodic agitation, a reduction
of Aβ1-40 ThT fluorescence was observed (Figure 1),
albeit with different degrees. This suggests a disruption
of the Aβ1-40 assembly process to form lesser amounts
of amyloid or thioflavin T active species. Also, the reduction in fluorescence relative to that of Aβ1-40 was
influenced greatly by the nature and terminal positioning of the polar residue added.
The AAMPs with N- and C-termini modified using
various polar groups showed a reduction in ThT fluorescence between 40 and 70% relative to that of Aβ1-40
after 1 week of incubation. In particular, AAMP-11
with polar Arg was the only AAMP with less than 50%
reduced fluorescence. The similarity in the percentage of
reduced ThT fluorescence indicates that comparable
amounts of ThT active structures were formed. When
based on ThT alone, one could argue that AAMP-11
is a better disrupter of Aβ fibril formation than the
other AAMPs (AAMP-12, AAMP-13, AAMP-14,
and AAMP-15) incorporating a polar group on both
termini. Also, a concentration dependent experiment
was carried out to determine the stoichiometric concentration inhibition mechanism using AAMP-14. We found
that AAMP-14 only disrupts at stoichiometric concentrations or molar excess with reduced ThT fluorescence
of >50% relative to that of Aβ1-40 alone, in contrast
with only 20% reduced fluorescence with substoichiometric ratios (see Supporting Information, Figure S1).
Interestingly, mitigators with polar residues placed
on only the C-terminus had an increased reduction in
r 2010 American Chemical Society

Effect of Various AAMPs on Aβ1-40 CD Spectra

The effect of RRAA-AAMPs on Aβ1-40 assembly
into β-sheet structure was examined using far-UV
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Effect of AAMPs with Polar Groups Added
to Both N- and C-termini on Aβ1-40 Fibril
Formation

The Aβ1-40 sample (40 μM) aged alone showed a
dense network of amyloid fibrils averaging 5.4 nm
in height and extending several micrometers in length
after 3 days of aging (Figure 3A). A predominantly
dense network of fibrils averaging 6.9 nm in height and
spanning several micrometers in length was observed
after 1 week of aging (Figure 3C). The fibrils that formed
are consistent with the Aβ1-40 aggregation process and
fit the proposed hierarchical assembly model (HAM
model) (42, 43). The spherical particles observed within a sea of fibrils after 3 days of aging are consistent
with results expected with periodic or continuous
sample agitation (44). The height analysis (Figure 3B
and D) shows that mature fibrils with diameter g7 nm
were predominant after 1 week of aging, which coincides with the results observed with maximum ThT
fluorescence.
When Aβ1-40 was aged with the equimolar ratio of
AAMPs (40 μM) incorporating differently charged
polar groups to both C- and N-termini, the normal
Aβ1-40 aggregation process was disrupted to form either
fibrils with different morphologies (appearance and
length) or spherical particles. A network of protofibrils
and fibrils (Figure 3E) were the major species observed
after 3 days of aging Aβ1-40 with Arg-containing
AAMP-11. The morphology of the AAMP-11 structures (Figure 3G) observed after 1 week of aging for the
most part did not change, except that an increase in
mean heights was observed as shown by the histogram
analysis (Figure 3F and H). Similarly, fibrils/protofibrils (Figure 3I) were observed after 3 days of aging
Aβ1-40 with equimolar AAMP-12 containing another
positively charged group (Lys). After 1 week of incubation of AAMP-12 (Figure 3K), there was increase in
both the mean height (Figure 3J and L) and surface
coverage of fibrils. Also, when Aβ1-40 was aged with
AAMP-13 containing a negatively charged Glu residue,
protofibrils and fibrils (Figure 3M) were observed after
3 days. Dense networks of beaded fibrils or protofibrils
(Figure 3O) were detected after 1 week of incubation
with AAMP-13 with height distribution (Figure 3N and
P) showing increase in particles size. Interestingly, spherical particles (Figure 3Q) were the major structures
observed after 3 days of aging Aβ1-40 with AAMP-14
incorporating a neutral MiniPEG group. No fibrillar
species (Figure S3, Supporting Information) were observed after 1 week of incubation; only spherical particle
clumps were observed resulting in an increase in height
as shown by the height histograms (Figure 3R and T).
When the number of Arg polar groups was increased to
three, as in AAMP-15, fibrils with lengths up to 1-2 μm
were observed for a 3 day sample as displayed in AFM

Figure 2. An example of a CD spectra for AAMP-14 alone, Aβ1-40
alone, and an Aβ1-40/AAMP-14 equimolar mixture after 1 week of
aging. (Final concentration was 40 μM for both Aβ1-40 and
AAMPs.)

circular dichroism (CD). The CD spectra of monomeric
AAMPs and Aβ1-40 displayed a strong minimum near
200 nm and maxima near 220 nm, consistent with
an unstructured conformation commonly referred to
as random coil conformation. After 1 week of aging
AAMPs alone at 37 °C while shaking, all exhibited
minima in their CD spectra around 200 nm, consistent
with unchanged random coil conformation. However,
the assembly of Aβ1-40 alone after 1 week of incubation
exhibited a CD spectra with minima around 217 nm
(Figure 2), consistent with aggregation into β-sheet rich
assemblies (25, 40). In contrast, when Aβ1-40 was aged
in the presence of equimolar AAMPs, an unusual CD
signature with characteristics of random coil and β sheet
was observed, consistent with our previous results for an
AAMP-1/Aβ1-40 mixture (see Supporting Information,
Figure S3 for another example of CD with different
AAMPs with identical results.) (25). This suggests that
our AAMPs delay or disrupt Aβ1-40 aggregation into
β-sheet rich assemblies.

Effect of AAMPs on Aβ Fibril Morphology
Samples of AAMPs alone, Aβ1-40 alone, and mixtures of Aβ1-40/AAMPs, which were prepared for the
same time intervals as those of the ThT fluorescence
assay, were examined using TEM and AFM. First,
samples for the mitigator aged alone were examined to
determine the morphology of the aggregates responsible
for the observed ThT fluorescence. This is important
because Aβ1-40 has been shown to aggregate via a nucleation dependent polymerization process (41, 42). Thus,
aggregates formed by AAMPs could act as seeds, rapidly
increasing the rate of Aβ assembly into fibrils. Peptide
mitigators were aged alone in PBS (50 mM at 37 °C with
periodic agitation) to investigate their self-aggregation.
Topographic images of various samples of AAMPs aged
for 1 week displayed sparse distribution of spherical aggregates on the mica surface (see Supporting Information, Figure S4) with mean heights ranging from 2-8 nm.
r 2010 American Chemical Society
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Figure 3. Mitigation of Aβ1-40 aggregation by AAMPs with polar groups added to both the C- and N-termini, as viewed by AFM topographs.
(A) Fibrils formed after 3 days of incubation by Aβ1-40 alone; (B) height analysis for A; (C) fibrils present after 1 week; (D) height analysis for
C; (E) fibrils formed after mitigation for 3 days by AAMP-11; (F) height analysis for E; (G) fibrils formed after 1 week; (H) height distribution
histogram for G; (I) mixture of spherical and protofibril structures after 3 days of mitigation by AAMP-12; (J) height analysis for I;
(K) spherical and short sized fibrils observed after 1 week; (L) height histogram for K; (M) protofibrils present after 3 days with AAMP-13;
(N) height analysis for M; (O) fibrils formed after 1 week; (P) height distribution analysis for O; (Q) spherical structures present after
mitigation for 3 days by AAMP-14; (R) height distribution for Q; (S) spherical structures observed after 1 week; (T) height analysis for S.
(The final concentration was 40 μM for both Aβ1-40 and AAMPs.)

r 2010 American Chemical Society
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which has been shown to be involved in the initial
process of Aβ assembly.

topographs (Figure 4A). The fibrils observed after 1 week
of incubation (Figure 4C) had increased height, as shown
by the cursor analysis (Figure 4B and D).
Fibrils were observed to form from aging mixtures of
Aβ1-40 with AAMP-11 (Figure 3E), which is in disagreement with published results where fibrils were not
detected (31). The difference in morphology of the
particles that formed could be attributed to differences
in the aging conditions that were employed. Sample
agitation is widely used to expedite amyloid fibril formation. This implies that under quiescent conditions
AAMP-11 disrupts fibril formation; however, it only
alters Aβ1-40 fibril morphology when aggregation rates
are increased by agitation. A mixture of short fibrils with
lengths spanning few micrometers and linear structures
with protofibrillar morphology were observed with
AAMP-12 incorporating positively charged Lys. Both
AAMP-11 and AAMP-12 alter the Aβ1-40 fibrillization
pathway forming fibrils that are short in length, more
branched, and with lower mean height as compared to
those of Aβ1-40 fibrils. Surprisingly, this is consistent
with SPR studies that showed mitigators (designed also
from the KLVFF core) with Lys and Arg polar residues
had identical binding affinities for immobilized Aβ10-35.
However, a dense network of fibrils (Figure 3O) with a
beaded morphology was observed when Aβ1-40 was
aged with AAMP-13 containing negatively charged Glu
after 1 week of incubation. The dense network of beaded
fibrils observed in AAMP-13 as compared to that in
AAMP-12 and AAMP-11 suggests that AAMP-13 is a
weaker disrupter of Aβ1-40 fibril formation. It is also
consistent with findings by Murphy and co-workers
from SPR studies that showed lower binding affinity
for Aβ10-35 from mitigators with negatively charged
polar groups (30). The lower binding affinities observed
from mitigators with negatively charged polar groups
was postulated to be possibly from Coulombic repulsions between the negatively charged polar groups in the
mitigator (Glu) and negatively charged residues in Aβ
(Glu and Asp) (12). In contrast, spherical particles with
diameters up to nearly 0.2 μm were observed from aging
Aβ1-40 in the presence of AAMP-14 (Figure 3Q) with
the MiniPEG (neutral) group. The MiniPeg group is a
glycol chain and increases the overall hydrophobicity of
the peptide. Thus, in this case increased hydrophobicity
is more of a factor as compared to Coulombic interaction (AAMP-11 and AAMP-12) because Aβ assembly is
initially controlled by hydrophobic interactions. Contrary to results observed for AAMP-14, increasing the
overall hydrophilicity of the peptide by the addition of
more positively charged Arg for AAMP-15 (three) as
compared to AAMP-11 (one) did not necessarily lead to
increased disruptive properties, as fibrils were the predominant species observed for both. This suggests the
importance of the overall hydrophobicity of the peptide,
r 2010 American Chemical Society

Effect of AAMPs with Polar Groups Added
to the N- or C-Terminus on Aβ1-40 Fibril
Formation
Surprisingly, AAMPs with polar groups added to
only the C-terminus produced particles with a different
morphology as compared to those with polar groups
added to both termini. For instance, spherical particles
(Figure 4E) were the predominant structures observed
from aging Aβ1-40 with AAMP-16 incorporating
Arg on the C-terminus. The height of these particles
(Figure 4G) increased up to 100 nm after 1 week of
incubation, as shown by height distributions (Figure 4F
and H). Mixtures of protofibrils and spherical particles
(Figure 4I) were observed after 3 days of aging Aβ1-40 in
the presence of AAMP-17 containing the neutral MiniPEG group. After 1 week of aging, spherical and linear
particles (Figure 4K) with increased heights (Figure 4J
and L) were observed. Also, when Aβ1-40 was aged with
AAMP-18 containing another positively charged group
(Lys), spherical particles and protofibrils (Figure 4M)
were detected for samples imaged after 3 days. Predominantly, fibrils (Figure 4O) were observed after 1 week
of incubation of AAMP-18 exhibiting an increased
height distribution as compared to that of spherical/
protofibrils observed after 3 days of aging (Figure 4N).
When Aβ1-40 was aged in the presence of AAMP-19
with polar groups added to the N-terminus, a mixture of
spherical and fibrillar structures (Figure 4Q) were observed for samples after 3 days of aging. Predominantly,
fibrils spanning a few micrometers (Figure 4S, Supporting Information) and even distribution (Figure 4T) from
those of Aβ were observed from samples taken after
1 week of aging.
Modification of only the C-terminal of AAMPs with
positively charged groups as in AAMP-16 and AAMP17 led to the disruption in forming fibrils to produce
either nonfibrillar structures or fibrils with different
morphologies (fibril length, fibril diameter, and fibril
entanglement) as compared to the structure of Aβ alone.
Analogues of KLVF with C-terminal modification with
Arg or Lys have been shown to have significantly larger
binding affinities for Aβ (30). Thus, the slight changes
observed for the morphology of the particles could be
related to the differences in the side chain functionality of the polar groups, where Arg has a more stable
positive charge from delocalization as compared to that
of Lys. When the positively charged residue is replaced
with a neutral group (MiniPEG), similar disruption
was observed and could be attributed to enhancing
hydrophobic-hydrophobic interactions between Aβ
and AAMP-17. Mitigators with their N- or C-terminus
modified with the same positively charged polar amino
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Figure 4. Disruption of Aβ1-40 fibril formation by AAMPs with polar groups added to the C- or N-terminus, characterized by tapping mode
AFM. (A) Views of short fibrils after 3 days aging Aβ1-40 in the presence of AAMP-15; (B) corresponding height distribution for A; (C) after
1 week; (D) height analysis for C; (E) spherical structures detected after 1 week of aging an Aβ1-40/AAMP-16 mixture; (F) corresponding height
distribution; (G) after 1 week; (H) height distribution analysis for G; (I) views of spherical and protofibrils formed by an Aβ1-40/AAMP-17
mixture after 3 days of aging; (J) corresponding height analysis; (K) after 1 week; (L) height analysis for K; (M) views of spherical particles and
protofibrils formed by Aβ1-40 aggregation mitigation by AAMP-18 after 3 days of aging; (N) corresponding height distribution; (O) fibrils
detected after 1 week; (P) height analysis for O. (Q) Spherical aggregates and protofibrils observed after 3 days of Aβ1-40 mitigation by
AAMP-19; (R) height distribution histogram for Q; (S) fibrils were present after 1 week of aging; (T) height analysis for S.
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Figure 5. Disruption of Aβ1-40 fibril formation by RRAAs-containing AAMPs. (A) Protofibrils and spherical structures observed after 3 days
of aging Aβ1-40 in the presence of AAMP-20; (B) height distribution for A; (C) spherical structures and fibrils (background) observed
after 1 week; (D) corresponding height analysis for C; (E) views of fibrils with some spherical structures detected after 3 days of aging the
AB1-40/AAMP-21 mixture; (F) corresponding height distribution; (G) after 1 week; (H) height distribution analysis for G; (I) spherical
structures observed for the Aβ1-40/AAMP-22 mixture after 3 days of aging; (J) corresponding height analysis; (K) spherical and linear
aggregates after 1 week; (L) height analysis for K.

1 week of incubation as discerned from height distribution analysis (Figure 5B and D). Mixtures of spherical
aggregates and fibrils/protofibrils (Figure 5E and G)
were observed from aging Dibg-containing AAMP-21
after 3 and 7 days of incubation. The height distribution
of the particles increased over the same time (Figure 5F
and H). When Aβ1-40 was aged in the presence of
AAMP-22 incorporating two RRAAs, spherical particles (Figure 5I) were observed exclusively after 3 days,
while spherical and linear particles (Figure 5K) were
observed after 1 week of aging. The diameters and
distribution of the particles increased at longer aging
times as shown by height analysis (Figure 5J and L).
Spherical and linear structures (Figure 6A and C) were
observed in AFM topographs of samples after three
days and 1 week of incubating Aβ1-40 in the presence of
AAMP-23, incorporating Dpg and three lysine residues
added to both termini.

acid residue altered Aβ fibrillization, forming particles
with different morphology. For instance, fibrils were
predominantly formed in AAMP-19 as compared to
spherical particles in AAMP-16 with N- and C-terminal
modified with Arg, respectively. This correlates also with
binding studies that showed AAMPs with Lys added to
the N-terminus had 3-fold lower binding affinities as
compared to AAMPs with Lys added to C-terminus.

Effect of rrAA-AAMPs with Polar Groups
Added to the C-Terminus on Aβ1-40 Fibril Formation

Analogues that incorporate RRAAs were also tested
to investigate the effects of varying both RRAAs
and polar groups on the morphology of Aβ-AAMP
aggregate. Spherical aggregates and isolated protofibrils (Figure 5A) were observed with Dpg-containing
AAMP-20 after 3 days of aging. Spherical aggregates
(Figure 5C) had grown to ∼100 nm in diameter after
r 2010 American Chemical Society
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Figure 6. Effects of RRAAs-containing AAMPs on Aβ1-40 fibril formation. (A) Protofibrils and spherical structures were observed after 3 days
of aging Aβ1-40 in the presence of AAMP-23; (B) height distribution for A; (C) spherical structures and linear structures observed after 1 week;
(D) corresponding height analysis; (E) spherical structures observed after 1 week of aging the Aβ1-40/AAMP-24 mixture; (F) height
distribution analysis for E; (G) rod-like fibrils and spherical aggregates observed after 1 week; (H) corresponding histogram analysis;
(I) spherical and protofibrillar structures observed after aging Aβ1-40/AAMP-25 for 3 days; (J) corresponding height analysis; (K) after
1 week (L); height analysis for K.

This suggests synergistic contributions from both RRAAs
as well as polar groups on the disruption of Aβ1-40 fibril
formation. This is consistent with the increased solubility
of Aβ/AAMP aggregate and steric factors, crucial in our
mitigator design.
Spherical structures (Figure 6E) were observed after
3 days of aging a mixture of Αβ1-40 and AAMP-24.
After 1 week of incubation, spherical aggregates and
protofibrils or linear structures (Figure 6G) were the
predominant structures. However, after 3 days of incubation of an Aβ1-40/AAMP-25 mixture, spherical aggregates and protofibrils (Figure 6I) were observed. After
1 week of aging, fibrils (Figure 6K) were more abundant.
For all the AAMPs, particles that formed were observed
to increase in height after longer aging, as shown by
height distributions (Figure 6B, D, F, H, J, and L).
The different morphologies of the particles observed
with AAMP-24 as compared to those in AAMP-25
can be attributed to the steric difference between the

AAMP-20 and AAMP-21 are similar in design with
AAMP-18 and AAMP-12 except for RRAA incorporated in their core. Mixtures of spherical aggregates and
fibrils were observed with both AAMP-20 and AAMP21 with diameters of spherical aggregates spanning up
to 0.1 μm as compared to those of primarily fibrils for
AAMP-18 and AAMP-12, although with different morphologies as compared to those of Aβ1-40. When the
number of Lys were increased to three and another
RRAAs introduced as in AAMP-22, compared to
AAMP-20 with only one Lys and RRAA, no fibrillar
structures were observed. This is also consistent with the
80% reduced fluorescence observed relative to that of
Aβ1-40. Also, increasing the length of polar residues on
each termini to three, as in AAMP-23, resulted in the
disruption of fibrils as compared to AAMP-20 (with one
polar group and similar RRAAs) and AAMP-15 (with
no RRAAs but same number of polar groups), both
showing fibrils as major species after 1 week of incubation.
r 2010 American Chemical Society
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RRAAs. Mixtures of spherical particles and protofibrils
were formed with AAMP-24, which contains more
sterically hindered Dibg (isobutyl side chains) as compared to the fibrils in AAMP-25, which incorporate Dpg
(n-propyl side chains). This highlights the important
role of steric hindrance in the mechanisms (blocking
face of aggregation) for disruption of Aβ fibrillization.
Also, the morphologies of resultant assemblies were
confirmed with TEM (see Supporting Information,
Figure S5).

Disassembly of Preformed Fibrils
It has been shown that the presence of fibrils in the
brain nucleates further deposition of plaques in AD (45).
It was previously stated that a dynamic equilibrium
exists between monomers/dimers and fibrils (22, 46, 47).
This makes agents that induce fibril disassembly an
attractive source for the development of new therapeutics that will reduce or eliminate plaques in the brain.
Previously, β-sheet breaker (22) and N-methylated peptides (15, 46) have been shown to also disassemble
preformed fibrils. Herein, we evaluate also whether
the designed AAMPs disassemble Aβ preformed fibrils.
Mature fibrils were formed by incubating Aβ1-40
for 1 week at 37 °C in PBS (pH 7.4) while agitating.
Equimolar mixtures of Aβ1-40 preformed fibrils and
AAMPs were aged for 24 h to evaluate their potential for
disassembly. The extent to which AAMPs induced fibril
disassembly was monitored using ThT fluorescence, as
well as with images acquired with AFM and TEM.
Results of ThT fluorescence are shown in Figure 7 as
the percentage relative to that of Aβ1-40.
Various AAMPs exhibit reduced fluorescence of
more than 50% relative to that of Aβ1-40. The N-methylated control peptide Aβ16-22m, which has been
shown to disassemble fibrils, displayed 40% reduced
fluorescence (15). On the basis of ThT fluorescence only,
various AAMPs tested exhibited reduced fluorescence
comparable to that of the N-methylated control peptide. After 24 h, there is no significant difference in
ThT fluorescence observed for AAMPs incorporating
polar groups on the N-and C-termini (AAMP-11-15),
C-terminus (AAMP-16-18), N-terminus (AAMP-19),
or RRAA-containing AAMPs (AAMP-20-25). It should
also be noted that the reduced fluorescence exhibited
by the various AAMPs do not necessarily indicate the
absence of fibrils. This is because inhibitor or disrupter
molecules can bind to fibrils displacing the bound ThT
molecule resulting in reduced fluorescence.

Figure 7. Fibril disassembly by various AAMPs as monitored
by ThT fluorescence, presented as the percent relative to that
of Aβ1-40.

A dense network of fibrils with a mean height of 7.9 nm
was observed from a topographic AFM image of Aβ1-40
sample after 1 week of aging (Figure 8A). Similar observations were found with TEM micrographs, which
displayed fibrils spanning several micrometers in length
(data not shown). Fibrils and protofibrils were the major
structures observed with the disassembly of preformed
fibrils by AAMP-11 (Figure 8C), AAMP-12 (Figure 8E),
and AAMP-15 (Figure 8K), which all have polar groups
added to both the C- and N-termini. Spherical aggregates
were the main structures observed after the disassembly of
preformed fibrils by AAMP-13 (Figure 8G) and AAMP14 (Figure 8I), which incorporate Glu and PEG chains,
respectively, into the C- and N-termini. Predominantly,
intact fibrils and isolated spherical particles were the
major products observed for the disassembly of preformed fibrils by AAMP-16 (Figure 8M), AAMP-17
(Figure 8O), and AAMP-18 (Figure 8Q) with different
polar groups added only to the C-terminus. Partially disassembled fibrils were observed for AAMP-19
(Figure 8S) with polar groups added to only the
N-terminus. Figure 8B, D, F, H, J, L, N, P, R, and
T shows the corresponding height distributions from
an analysis of multiple cursor profiles.
Fibrillar structures were the predominant structures
formed from the disassembly by AAMP-11, AAMP-12,
AAMP-15, AAMP-16, AAMP-17, AAMP-18, and
AAMP-19. However, the surface coverage and morphology (distribution, appearance, length, etc.) of the fibrillar
structures formed indicates partial disassembly. For instance, fibrillar structures observed from Aβ1-40 fibril
disassembly by AAMP-15, AAMP-17, and AAMP-18
showed nucleation units along the fibril length. This is
an indication of immature fibrils or protofibrillar structures, which are precursors of mature fibril formation.

Size and Morphology of Structures Formed
by the Disassembly of Preformed Fibrils by
Various AAMPs
Parallel AFM experiments were conducted for samples
prepared at the same time as those for ThT fluorescence.
r 2010 American Chemical Society
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Figure 8. Disassembly of preformed fibrils of Aβ1-40. (A) Control sample of Aβ1-40 fibrils. (B) Corresponding height histogram. (C) Fibrils
and spherical structures after disassembly by AAMP-11. (D) Histogram analysis for C. (E) Partial disassembly by AAMP-12. (F) Height
histogram analysis for E. (G) Spherical particles formed by AAMP-13 fibril disassembly. (H) Height analysis for G. (I) Spherical aggregates
and fibrils (background) formed from disassembly by AAMP-14. (J) Corresponding height analysis. (K) Isolated fibrils present from
disassembly by AAMP-15. (L) Height histogram for K. (M) Mixture of short and long fibrils observed from disassembly by AAMP-16.
(N) Corresponding height analysis. (O) Fibrils showing beaded sections for Aβ1-40 fibril disassembly by AAMP-17. (P) Corresponding
height histogram. (Q) Fibrils showing nucleation units for mature fibrils after disassembly by AAMP-18. (R) Corresponding height
analysis. (S) Partial preformed fibril disassembly observed with AAMP-19. (T) Height histogram for O.
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Figure 9. Disassembly of Aβ1-40 preformed fibrils imaged using tapping mode AFM. (A) Fibril disassembly by AAMP-20. (B) Corresponding
height histogram. (C) Spherical structures were observed with disassembly by AAMP-21. (D) Height analysis for C. (E) Spherical structures
with disassembly by AAMP-22. (F) Corresponding height histogram. (G) Fibrils with beaded morphology observed from disassembly by
AAMP-23. (H) Height analysis for G. (I) Spherical aggregates and isolated protofibrils formed from disassembly by AAMP-24. (J) Height
analysis for I. (K) Fibrils and some spherical species observed from fibril disassembly by AAMP-25. (L) Corresponding height analysis.
(The final concentration was 40 μM for both Aβ1-40 and AAMPs.)

height of 11.2 nm were the major structures of disassembly
when both RRAAs (Dpg and Dibg) were incorporated in
a mitigator as in AAMP-22. Also, extending the oligolysine chain on both termini as in Dpg-containing AAMP23 (Figure 9G) evidenced no fibrils in AFM images,
suggesting that the oligolysine chain plays a role in the
disassembly of preformed fibrils. Figure 9B, D, F, H, J,
and L provides corresponding analysis of the height
distribution of particles from AFM cursor measurements.
The steric nature of RRAAs has a role in the disassembly process as evidenced from spherical particles
formed by the diisobutyl side chain containing AAMP21 and AAMP-24, as compared to fibrillar structures
formed with a dipropyl side chain containing AAMP-20
and AAMP-25. The distribution of RRAAs in the
KLVFF motif is a factor in the disassembly of preformed fibrils. For instance, fibrillar structures were the
major species formed by AAMPs incorporating RRAAs

In addition, there is evidence of fibril breakage as shown
by the presence of fibrils with lengths less than a micrometer (AAMP-16) as compared to those of preformed
Aβ1-40 fibrils which span several micrometers. The only
exceptions are AAMP-13 and AAMP-14 where spherical
particles with diameters up to 0.1 μm were formed.
Interestingly, these two mitigators incorporate oligolysine and PEG chains, respectively, on both termini. This
underscores the contributions of terminal chains either
hydrophobic or hydrophilic in the mechanism of disassembly for preformed fibrils.
When RRAA-containing AAMPs were mixed with
preformed fibrils, fibrils/protofibrils (Figure 9A and K)
were the major species with disassembly by Dpgcontaining AAMP-20 and AAMP25 as compared to
mainly spherical particles (Figure 9C and I) observed
with Dibg containing AAMP-21 and AAMP-24. Interestingly, spherical particles (Figure 9E) with a mean
r 2010 American Chemical Society
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Table 2. Summary of Results from the Assembly and Disassembly of Aβ1-40 in the Presence of Various Mitigators
assembly

disassembly

3 days
AAMPs

aggregate type

1 week
mean height (nm)

aggregate type

24 h
mean height (nm)

aggregate type

mean height

Aβ1-40

fibrils

5(2

fibrils

7(4

fibrils

8(3

AAMP-11

protofibrils/fibrils

4(2

protofibrils/fibrils

7(3

spherical/protofibrils

7(4

AAMP-12

protofibrils/spherical

5(3

rod shaped fibrils

8(3

spherical/fibrils

6(3

AAMP-13
AAMP-14

protofibrils/fibrils
spherical

6(3
28 ( 13

protofibrils/beaded fibrils
spherical

7.2 ( 2
40 ( 21

spherical
protofibrils/spherical

16 ( 11
20 ( 11
7(4

AAMP-15

protofibril/linear

4(2

protofibril/rod like fibrils

6(2

spherical

AAMP-16

spherical

21 ( 10

spherical

36 ( 15

fibrils/spherical

8(5

AAMP-17

spherical

8(4

spherical

10 ( 4

spherical/protofibrils

7(4

AAMP-18

protofibrils/spherical

6(3

fibrils

8(3

protofibrils/fibrils

12 ( 7

AAMP-19

spherical/protofibrils

6(3

linear/fibrils

10 ( 4

fibrils

5(4

AAMP-20

protofibrils

7(3

spherical/linear

24 ( 12

protofibrils/fibrils

10 ( 5

AAMP-21
AAMP-22

protofibrils
spherical

5(3
6(2

fibrils
spherical

8(5
6(3

spherical/protofibrils
spherical/linear

7(4
11 ( 7
13 ( 8

AAMP-23

spherical/linear

5(2

linear/spherical

10 ( 5

spherical

AAMP-24

spherical

9(4

spherical, linear

6(2

spherical/protofibrils

8(3

AAMP-25

spherical, protofibrils

6(3

fibrils

12 ( 7

fibrils

8(4

Aβ16-22

spherical

11 ( 5

spherical/fibrils

16 ( 10

spherical

36 ( 20

N- and C- termini. For instance, mitigator AAMP-16
with the C-terminal modified with Arg was found to
be a potent disrupter of Aβ1-40 fibril assembly, forming
spherical aggregates. This is consistent with the previously reported use of Arg to solubilize inhibitors of
Aβ1-42 (48) and R-synuclein (49) fibrillogenesis, and
protect differentiated SHSY-5Y neuroblastoma cells
against Aβ toxicity. Also, as a result of terminal modifications with different polar groups, potent mitigators
of Aβ1-40 fibrillization were found where the most
interesting are the ones with neutral MiniPEG polar
groups. This is because previous designs mostly used
positively charged amino acids such as Lys or Arg which
makes peptide delivery through the brain barrier difficult, leading to accumulation and toxicity as previously
observed at high doses with our original mitigator
with six Lys residues (32). Thus, this study serves as
a foundation for the future design of more effective
peptides with increased systemic bioavailability and for
optimal use in vivo.
Smaller-sized spherical particles were observed for
disruption by AAMP-17 as compared to AAMP-14,
with the C-terminus or the C- and N-termini modified with MiniPEG, respectively. This indicates that
the N-terminal modification enhances aggregation to
form larger assemblies. We have previously reported
similar results where large sizes of particles formed
with N-terminal modification of RRAA-KLVFF compared to C-terminal modification using six oligolysine chains (25). The particle size difference is closely

outside the KLVFF region (AAMP-20 and AAMP-25)
as compared to the spherical structures observed with
RRAAs placed in the KLVFF core, which is consistent
with our previous observation (27). Also, increasing the
hydrophobicity or steric nature of the mitigator by
incorporating two RRAA as in AAMP-22 induces disassembly of preformed fibrils to form spherical particles
exclusively. Although not conclusive, greater surface
coverage of disassembled fibrils was observed with
AAMP-20 than in the case of AAMP-25 with one and
three C-terminal lysines, respectively. This suggests
that the length of the lysine chain plays a role in the
disassembly process. The same trend of the lysine
chain length effect is also seen with AAMP-23 with
three lysines added to both termini, where no fibrils
were detected as expected suggesting that the added
chain also contributes to the disassembly of preformed fibrils. This shows that the disassembly of
preformed fibrils is a synergistic combination of the
influences of RRAAs as well the length of the polar
groups.
A comparison of results for the various AAMPs from
analyses of the AFM images observed for the assembly
and disassembly of the various mitigators are summarized in Table 2. Our studies demonstrate that terminal
modifications of the mitigator core sequence (KLVFF)
with different polar groups altered Aβ fibrillization
yielding particles with different morphologies and sizes.
Different results were obtained with modification of
only the C-terminus as compared to changes for both
r 2010 American Chemical Society
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previously shown to disassemble preformed fibrils (15).
The N-methylated Aβ16-22m disassembled preformed
fibrils and yielded large spherical aggregates with mean
heights of 35.6 nm. In contrast, smaller aggregates were
observed with RRAA-AAMPs. The difference in the
height of assemblies that formed can only be attributable
to the added polar groups. Thus, polar groups play a role
in determining the size of assemblies formed. We hypothesize that substitution of the hydrogen atom on the
R-carbon of certain amino acids in the critical KLVFF
region with an alkyl substituent yields a more hydrophobic peptide. Initial assembly of Aβ oligomers is
controlled by the hydrophobic side chains. Thus, increasing the hydrophobicity of this region should also
enhance interactions between Aβ and the mitigator,
leading to both the disruption of Aβ assembly into fibrils
as well as the disassembly of preformed fibrils. The
mechanism of disassembly is believed to occur by mitigator monomers binding to the end of fibrils and shifting
equilibrium toward prefibrillar assemblies. Thus, this
study can guide future designs of dissolution agents.
In addition, there is increasing evidence that equilibrium exists between fibrils and monomers (47, 52, 53).
Mitigator KLVFFK6 was previously shown by Murphy
and co-workers to alter the Aβ1-40 fibrillization process,
forming fibrils with different morphologies that were
protective against Aβ cytotoxicity. The nontoxic nature
of these fibrils is believed to be because they are stable to
the equilibrium change unlike Aβ fibrils which are in
constant equilibrium with the more toxic oligomeric
assemblies (13). Thus, future cytotoxicity experiments
on our mitigators that form fibrils with morphologies
different from those of Aβ1-40 fibrils will further provide
a basis for the design of mitigators that may result in
fibrils that are stable and protect against neurotoxicity.

associated with the disruption of the hydrophobic
C-terminal group (50), which has more impact on
aggregation than the hydrophilic N-terminal (51).
The different morphologies of particles formed with
AAMP-19 (fibrils) and AAMP-16 (spherical aggregates) are attributable of the N- and C-terminal modifications, respectively. Through SPR binding studies,
Murphy and co-workers have shown that AAMPs with
positively charged polar groups placed on the N-terminus have a 3-fold lower affinity for immobilized Aβ10-35
than the ones placed on the C-terminus (30). From SPR
and our AFM studies, it can be concluded that mitigators with a higher affinity for the target Aβ1-40 are better
disrupters of Aβ fibrillization.
The AAMPs incorporating RRAAs were better disrupters of Aβ fibrillization as compared to AAMPs
without RRAAs. For instance, linear structures and
fibrils were formed from the incubation of Aβ1-40
in the presence of RRAA-containing AAMP-20 and
AAMP-18, respectively. This is because incorporating
RRAAs in the AAMP core forces the peptide to adopt
an extended conformation that is ideal for interacting
with Aβ1-40 through side chain-side chain hydrophobic interactions. Also, incorporation of RRAAs into the
mitigator core increases its hydrophobic character
and, in essence, impacts Aβ1-40 assembly since the
initial aggregation is controlled by hydrophobic interactions. Mitigator AAMP-22 incorporating two
RRAAs in the KLVFF motif and containing three
lysines on the C-terminus was found to have similar
disruptive properties as compared to our previously
reported AAMP-3 (27) with six lysines (25). This
shows that the number of lysines can be reduced
without affecting the solubility and disruptive properties of the mitigator.
Mitigators incorporating RRAAs that disrupted fibril
formation also disassembled preformed fibrils, which
underscore the importance of steric used in the design of
these mitigators. This was compared to the primary
fibrils/protofibrils observed in AAMPs without RRAAs
as with AFM and TEM data. Mitigators that disassembled preformed fibrils to produce prefibrillar assemblies suggest that equilibrium exists between fibrils and
prefibrillar aggregates. Topographic AFM data of the
disassembly of preformed fibrils show agreement with
data from ThT fluorescence. The lower percent ThT
fluorescence exhibited by AAMP/Aβ1-40 mixtures is
consistent with the observations of lower surface coverage of fibrils. Peptides, which have their termini modified
with Lys, Arg, Glu, and glycol chains have been shown
to be effective at disrupting fibril formation as well as
protecting against neuronal toxicity (15, 18, 19, 31). Mitigators, AAMP-21, AAMP-22, and AAMP-23 induced
the disassembly of preformed fibrils to a degree similar to
that of N-methylated peptide, Aβ16-22m, which was
r 2010 American Chemical Society

Methods
Peptide Synthesis
The various AAMPs were synthesized from 9H-fluoren9-ylmethoxycarbonyl (Fmoc) amino acids using solid phase
peptide synthesis on PAL-PEG-PS resin or Rink amide
ChemMatrix resin. Coupling of individual amino acids was
achieved using previously described methods (54-56).
After the last amino acid was coupled, the peptides were
deprotected and cleaved from the resin by treatment with
cleavage cocktail [88% trifluoroacetic acid (TFA), 5%
H2O, 5% phenol, and 2% TIPS]. The peptides were precipitated from the cocktail solution with cold diethyl ether
and then dissolved in water/acetonitrile, and lyophilized.
The crude peptides were purified by reversed phase HPLC
using a 10% to 70% B linear gradient over 60 min [Waters
C4 100 Å column using solvent A (water and 0.1% TFA)
and solvent B (acetonitrile and 0.1% TFA)]. The purity of
the peptides was checked by analytical HPLC and the
masses confirmed by ESI-MS. The percent peptide content
was verified by amino acid analysis.
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Supporting Information Available

Peptide Monomerization
Lyophilized Aβ1-40 purchased from Invitrogen Corporation (Carlsbad, CA, USA) was pretreated to form monomeric
solutions following our previously published protocol (57).
Briefly, Aβ1-40 was dissolved in neat TFA at 1 mg/mL,
sonicated for 10-20 min, and removed using a centrivac,
yielding a dark yellow oil. The dark oil was dissolved in 1 mL
of hexafluoroisopropanol (HFIP) at 1 mg/mL and aged at
37 °C for 1 h, after which HFIP was removed, yielding a white
powder. The white powder was redissolved in HFIP and split
into 0.25 mg fractions based on the assumption that at this
point in the preparation the mass of Aβ1-40 was 50%. The
0.25 mg fractions were aged for 1 h upon which HFIP was
removed, and the white powder product was lyophilized
overnight. The lyophilized white powder was dissolved in
2 mM NaOH and PBS (100 mM and 300 mM NaCl,
pH 7.4) at 1:1 and centrifuged for 20 min at 13,000g, which
was then ready for the aggregation assay. The supernatant
was subjected to amino acid analysis to determine the net
peptide content.

Concentration dependent study of the assembly of Aβ1-40 in
the presence of AAMP-14; assembly of Aβ1-42 in the presence of RRAA-AAMPs; example CD signatures obtained
for Aβ1-40 mitigation; spherical aggregates observed after
one week of aging the various AAMPs alone; morphologies
of various surface structures observed after one week of
aging Aβ1-40 in the presence of various AAMPs with and
without RRAAs. This material is available free of charge via
the Internet at http://pubs.acs.org.
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